Thomas Gaberel1, Clement Gakuba, Marie Hebert, Axel Montagne, Veronique Agin, Marina Rubio, Evelyne Emery, Denis Vivien, Maxime Gauberti. 1. From the Inserm, UMR-S U919, Serine Proteases and Pathophysiology of the Neurovascular Unit, GIP Cyceron, University Caen Lower-Normandy, Caen, France (T.G., C.G., A.M., V.A., M.R., E.E., D.V., M.G.); and Department of Neurosurgery (T.G., E.E.), Department of Anesthesiology and Critical Care Medicine (M.H.), and Biostatistics and Clinical Research Unit (M.R.), Caen University Hospital, Caen, France.
Abstract
BACKGROUND AND PURPOSE: The aim of the present study was to investigate the effects of normobaric oxygen (NBO) therapy on T2*-weighted images of intracranial hemorrhages (ICHs). METHODS: Two common models of ICH were performed in mice, and longitudinal T2*-weighted images of the hematomas were acquired under normoxia or NBO. The effects of NBO were also investigated on perfusion-weighted imaging, susceptibility-weighted imaging, and molecular imaging of vascular cell adhesion molecule-1 after ICH. Last, we performed neurological testing, including neuroscore, actimetry, and gait analysis (Catwalk), to study the influence of NBO on neurological outcome of mice presenting ICH. RESULTS: Our results demonstrated that NBO, even during a short period of time, dramatically reduces the sensitivity of T2*-weighted imaging to detect ICH. Moreover, we provide evidence that the disappearance of ICH on T2*-weighted imaging could be used to improve accuracy of perfusion-weighted imaging and to allow molecular imaging after ICH. Importantly, a 30-minute NBO preparation 24 hours after ICH onset does not influence neurological outcome. CONCLUSIONS: We provide an experimental demonstration that NBO significantly affects T2*-weighted imaging in ICH. Although this phenomenon could lead to inaccurate assessment of ICH volume, it could also be safely used to allow perfusion-weighted imaging and molecular imaging.
BACKGROUND AND PURPOSE: The aim of the present study was to investigate the effects of normobaric oxygen (NBO) therapy on T2*-weighted images of intracranial hemorrhages (ICHs). METHODS: Two common models of ICH were performed in mice, and longitudinal T2*-weighted images of the hematomas were acquired under normoxia or NBO. The effects of NBO were also investigated on perfusion-weighted imaging, susceptibility-weighted imaging, and molecular imaging of vascular cell adhesion molecule-1 after ICH. Last, we performed neurological testing, including neuroscore, actimetry, and gait analysis (Catwalk), to study the influence of NBO on neurological outcome of mice presenting ICH. RESULTS: Our results demonstrated that NBO, even during a short period of time, dramatically reduces the sensitivity of T2*-weighted imaging to detect ICH. Moreover, we provide evidence that the disappearance of ICH on T2*-weighted imaging could be used to improve accuracy of perfusion-weighted imaging and to allow molecular imaging after ICH. Importantly, a 30-minute NBO preparation 24 hours after ICH onset does not influence neurological outcome. CONCLUSIONS: We provide an experimental demonstration that NBO significantly affects T2*-weighted imaging in ICH. Although this phenomenon could lead to inaccurate assessment of ICH volume, it could also be safely used to allow perfusion-weighted imaging and molecular imaging.
Entities:
Keywords:
behavior therapy; cerebral hemorrhage; magnetic resonance imaging; molecular imaging
Authors: Sara Martinez de Lizarrondo; Clément Gakuba; Bradley A Herbig; Yohann Repessé; Carine Ali; Cécile V Denis; Peter J Lenting; Emmanuel Touzé; Scott L Diamond; Denis Vivien; Maxime Gauberti Journal: Circulation Date: 2017-05-09 Impact factor: 29.690
Authors: Julie Belliere; Sara Martinez de Lizarrondo; Robin P Choudhury; Aurélien Quenault; Audrey Le Béhot; Christine Delage; Dominique Chauveau; Joost P Schanstra; Jean-Loup Bascands; Denis Vivien; Maxime Gauberti Journal: Theranostics Date: 2015-08-08 Impact factor: 11.556
Authors: Maxime Gauberti; Antoine P Fournier; Fabian Docagne; Denis Vivien; Sara Martinez de Lizarrondo Journal: Theranostics Date: 2018-02-02 Impact factor: 11.556